Ciphergen Announces Presentation of Data Demonstrating Use of Diagnostic Test to Monitor Blood Disorder
11 Diciembre 2006 - 8:00AM
PR Newswire (US)
FREMONT, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Ciphergen
Biosystems, Inc. (NASDAQ:CIPH) today announced that its clinical
development partner Ohio State University presented data
demonstrating the clinical utility of its assay to manage patients
with thrombotic thrombocytopenic purpura (TTP), a hematologic
disease. These findings were presented at the American Society of
Hematology 48th Annual Meeting in Orlando, Fla., December 9-12,
2006. "Continual monitoring, or testing, of the enzyme that is
deficient in patients with TTP aids physicians in determining
disease activity so that they may apply the proper course of
treatment," said Haifeng M. Wu, M.D., Assistant Professor of
Pathology and Medicine and Director of Clinical Coagulation
Laboratory at Ohio State University Medical Center. "In this
initial study population, our TTP assay helped us evaluate
recurrence of disease and patient response to therapy, resulting in
improved clinical outcome." Twenty-one patients treated with
concurrent cyclosporine and plasma exchange (CSA/PE) were monitored
using the SELDI-based test to measure response to therapy and to
determine appropriate course of treatment. Each patient was tested
weekly during the active disease phase and during initial clinical
remission. After achieving a sustained clinical remission, patients
were then tested quarterly. Continual laboratory monitoring, along
with clinical assessment, enabled physicians to make appropriate
adjustments to the treatment regimen, resulting in improved
clinical outcome. "These studies further contribute towards our
understanding of the pathogenesis of this disease," said Eric T.
Fung, M.D., Ph.D., Chief Scientific Officer for Ciphergen
Biosystems. "We intend to apply these promising results towards a
larger patient population to further validate the assays' clinical
utility for monitoring disease activity and for evaluating
treatment response in patients with TTP." About Thrombotic
Thrombocytopenic Purpura (TTP) TTP is a blood disorder
characterized by low platelets, low red blood cell count (caused by
premature breakdown of the cells), neurological abnormalities and
sometimes abnormalities in kidney function. In most cases, this
disease is caused by a deficiency in or auto-antibodies to an
enzyme called ADAMTS13, which cleaves von Willebrand Factor. Loss
of this enzyme causes platelet clumping and red blood cell
destruction that are the hallmarks of TTP. About the Collaboration
In November 2006, Ciphergen and OSU announced a collaborative
agreement to develop and clinically validate a diagnostic test to
detect TTP. Under the terms of the agreement, OSU and Ciphergen
will optimize the assay to measure enzyme and antibody inhibition
activity, and will jointly conduct multi-center studies to validate
the test. About Ciphergen Ciphergen Biosystems, Inc. is dedicated
to the discovery, development and commercialization of novel
high-value diagnostic tests that help physicians diagnose, treat
and improve outcomes for patients. Ciphergen, along with its
prestigious scientific collaborators, has ongoing diagnostic
programs in oncology/hematology, cardiology and women's health with
an initial focus in ovarian cancer. Based in Fremont, California,
more information about Ciphergen can be found on the Web at
http://www.ciphergen.com/. Safe Harbor Statement Note Regarding
Forward-Looking Statements: This press release contains
forward-looking statements. For purposes of the Private Securities
Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any
intent or obligation to update these forward-looking statements,
and claims the protection of the Safe Harbor for forward-looking
statements contained in the Act. Examples of such forward-looking
statements include statements regarding the development and
performance of a clinical diagnostic test for TTP and the potential
use of a particular assay in that test. Actual results may differ
materially from those projected in such forward-looking statements
due to various factors, including the possibility that Ciphergen
and its partner may not be able to further validate the clinical
diagnostic test for TTP or otherwise successfully develop such a
test. Investors should consult Ciphergen's filings with the
Securities and Exchange Commission, including its Form 10-Q filed
November 20, 2006, for further information regarding these and
other risks related to the Company's business. DATASOURCE:
Ciphergen Biosystems, Inc. CONTACT: Sue Carruthers, Investor
Relations of Ciphergen Biosystems, Inc., +1-510-505-2233; or Media:
Lori Murray of WeissComm Partners, +1-415-946-1070, for Ciphergen
Biosystems, Inc. Web site: http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024